Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Adding Renal table |
mNo edit summary |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Renal Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray}} | |||
'''Table 1 - Recurrent Genomic Alterations in AML Detected by Chromosomal Microarray (Literature Review)'''. This is a comprehensive list of CNAs and CN-LOH detectable by CMA testing with strong diagnostic, prognostic and treatment implications in AML. Table derived from Xu et al., 2018 [PMID: 32434132] with permission from Cancer Genetics. | |||
{| class="wikitable" | {| class="wikitable" | ||
| colspan="8" |'''WHO Classification''' | | colspan="8" |'''WHO Classification''' | ||
| Line 6: | Line 9: | ||
|'''Papillary RCC''' | |'''Papillary RCC''' | ||
'''Type 1''' | '''Type 1''' | ||
|'''Papillary RCC''' | |'''Papillary RCC''' | ||
| Line 20: | Line 23: | ||
|15-20% | |15-20% | ||
|15-20% | |15-20% | ||
| colspan="2" |1-5% | | colspan="2" | 1-5% | ||
|5% | | 5% | ||
|5% | | 5% | ||
|- | |- | ||
|'''Origin''' | |'''Origin''' | ||
| Line 41: | Line 44: | ||
|1p- (10%) [2; R] | |1p- (10%) [2; R] | ||
| | | | ||
|1p- (25%) [2; R] | | 1p- (25%) [2; R] | ||
| colspan="2" |1p- (30%) [3; R] | | colspan="2" |1p- (30%) [3; R] | ||
|'''-1''' (90%) '''[1; D]<sup>c</sup>''' | |'''-1''' (90%) '''[1; D]<sup>c</sup>''' | ||
| Line 96: | Line 99: | ||
|'''+7/+7,+7''' (84%) '''[1; D]<sup>c</sup>''' | |'''+7/+7,+7''' (84%) '''[1; D]<sup>c</sup>''' | ||
|'''+7''' (25%) '''[1; D]''' | |'''+7''' (25%) '''[1; D]''' | ||
| colspan="2" |+7 (30%) [3; R] | | colspan="2" | +7 (30%) [3; R] | ||
| | | | ||
| | | | ||
| Line 140: | Line 143: | ||
|<nowiki>+12 (52%) [2; R]</nowiki> | |<nowiki>+12 (52%) [2; R]</nowiki> | ||
|<nowiki>+12 (15%) [3; R]</nowiki> | |<nowiki>+12 (15%) [3; R]</nowiki> | ||
| colspan="2" |+12 (35%) [3; R] | | colspan="2" | +12 (35%) [3; R] | ||
| | | | ||
| | | | ||
| Line 164: | Line 167: | ||
| | | | ||
|<nowiki>-15 (15%) [3; R]</nowiki> | |<nowiki>-15 (15%) [3; R]</nowiki> | ||
| colspan="2" |-15 (15%) [3; R] | | colspan="2" | -15 (15%) [3; R] | ||
| | | | ||
| | | | ||
| Line 260: | Line 263: | ||
| colspan="8" |'''Mutations (SNVs, Indels) [level of evidence; clinical significance]''' | | colspan="8" |'''Mutations (SNVs, Indels) [level of evidence; clinical significance]''' | ||
|- | |- | ||
|Mutated | | Mutated | ||
in >20% | in >20% | ||
| Line 270: | Line 273: | ||
| | | | ||
|- | |- | ||
|Mutated | | Mutated | ||
in 10-20% | in 10-20% | ||